platinum has been researched along with Esophageal Neoplasms in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 9 (28.13) | 24.3611 |
| 2020's | 17 (53.13) | 2.80 |
| Authors | Studies |
|---|---|
| Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T | 1 |
| Dong, X; Jia, Y; Song, X; Song, Y; Wang, W; Yi, Y; Zhang, J | 1 |
| Hirota, M; Kawada, J; Kawakami, H; Kii, T; Kurokawa, Y; Matsuyama, J; Nomura, M; Ohta, T; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T | 1 |
| Boku, N; Chin, K; Ichimura, T; Kadowaki, S; Kitano, S; Kudo, T; Liu, J; Mitani, S; Muro, K; Ooki, A; Sakai, D; Satoh, T; Takashima, A; Thai, D; Yamaguchi, K; Zavodovskaya, M | 1 |
| Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T | 1 |
| Bai, Y; Li, E; Qian, J; Shi, D; Xu, J; Xu, N | 1 |
| Gibson, MK; Weidenbaum, C | 1 |
| Guo, Z; Jia, Y; Song, R; Wu, C; Zhang, R; Zhang, S; Zhang, X; Zhao, Y | 1 |
| Enzinger, PC; Guo, H; Joo, S; Meng, Y; Qu, T; Zhang, S; Zhong, Y | 1 |
| Brossart, P; Feldmann, G; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, MB; Sadeghlar, F; Sarria, GR; Sommer, N; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T | 1 |
| Dang, C; Li, K; Ma, R; Mo, C; Yin, J; Yuan, D; Zhang, Y; Zhu, K | 1 |
| Wang, CJ; Yin, MM; Zhao, WF; Zhao, Z | 1 |
| Ge, M; Jiang, B; Jiang, W; Song, K; Wang, S; Yan, X; Zhang, L; Zhang, S | 1 |
| Al-Chamali, H; Bird, T; Cox, C; Dorey, N; Gomberg, S; Goody, R; Hingorani, M; Hurt, C; Macgregor, U; Mukherjee, S; Owens, R; Pan, S; Parikh, S; Prince, S; Radhakrishna, G | 1 |
| Aguiar, MC; Botelho, MF; Brites, G; Brito, AF; Casalta-Lopes, J; Gonçalves, AC; Laranjo, M; Nascimento, BFO; Pereira, NAM; Pineiro, M; Pinho E Melo, TMVD; Sarmento-Ribeiro, AB | 1 |
| Casak, S; Cheng, J; Donoghue, M; Fashoyin-Aje, L; Goldberg, KB; Jiang, X; Khazraee, M; Lemery, S; Liu, J; Mushti, S; Pazdur, R; Pelosof, L; Saung, MT; Theoret, M; Zhao, H | 1 |
| Kato, S; Miwa, N; Saitoh, Y | 1 |
| Chai, T; Chen, S; Kang, M; Lin, J; Lin, W; Lin, Y; Shen, Z; Zhang, P; Zhang, Z | 1 |
| de Castria, TB; Fujiki, FK; Hoff, PMG; Takeda, FR; Victor, CR | 1 |
| Alakus, H; Bollschweiler, E; Drebber, U; Eberz, PM; Frazer, KA; Harismendy, O; Hölscher, AH; Lowy, AM; Maus, M; Metzger, R; Mönig, SP; Siffert, W; Warnecke-Eberz, U | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Abbassi-Ghadi, N; Begum, S; Biggs, J; Birkbak, NJ; Hanna, GB; Hochhauser, D; Horswell, S; Kumar, S; Matthews, N; McGranahan, N; Mitter, R; Murugaesu, N; Phillimore, B; Rowan, A; Salm, M; Swanton, C; Watkins, T; Wilson, GA | 1 |
| Bail, JP; Brigand, C; Collet, D; Gronnier, C; Lebreton, G; Luc, G; Mabrut, JY; Mariette, C; Meunier, B | 1 |
| Amadori, A; Battaglia, G; Bocus, P; Boldrin, E; Cagol, M; Castoro, C; Chiarion-Sileni, V; Malacrida, S; Rumiato, E; Ruol, A; Saggioro, D | 1 |
| Cheng, L; Jia, M; Qiu, L; Wang, M; Wei, Q; Xiang, J; Zhou, F; Zhu, M | 1 |
| Han, SM; Han, Y; Shi, SB; Tian, J; Wang, YS | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Asfaw, I; Buroker, T; Dindogru, A; Franklin, R; Hoschner, D; Knechtges, T; Leichman, L; Loh, JJ; Miller, P; Pietruk, T; Rosenberg, JC; Seydel, H; Steiger, Z; Torres, A; Vaishamapayan, G; Vaitkevicius, V; Wilson, RF | 1 |
| Ikeda, K; Ishida, K; Iwaya, T; Kawamura, H; Koeda, K; Maesawa, C; Saito, K; Sato, N; Takagane, A; Takiyama, I; Terashima, M; Yoshinari, H | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Kumada, K; Makuuchi, M; Midorikawa, T; Nemoto, H; Sanada, Y; Sasaya, S; Takeuchi, S; Takizawa, K; Uemichi, O; Yamaguchi, M; Yoshizawa, Y | 1 |
| Francois, E; Frenay, M; Milano, G; Namer, M; Troger, V | 1 |
4 review(s) available for platinum and Esophageal Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Platinum; Prospective Studies; Retrospective Studies; Taxoids | 2022 |
Approach to Localized Squamous Cell Cancer of the Esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Platinum; Quality of Life | 2022 |
Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Fluorouracil; Humans; Leukopenia; Lung Neoplasms; Platinum; Taxoids; Thrombocytopenia | 2022 |
Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies | 2020 |
4 trial(s) available for platinum and Esophageal Neoplasms
| Article | Year |
|---|---|
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Taxoids | 2022 |
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Japan; Matrix Metalloproteinase 9; Oxaliplatin; Platinum; Stomach Neoplasms | 2022 |
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Humans; Nivolumab; Platinum | 2021 |
Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kidney; Male; Middle Aged; Platinum; Stomach Neoplasms | 1998 |
24 other study(ies) available for platinum and Esophageal Neoplasms
| Article | Year |
|---|---|
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2022 |
Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies | 2022 |
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Radiotherapy, Conformal; Retrospective Studies | 2022 |
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cost-Benefit Analysis; Delivery of Health Care; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Platinum; Quality-Adjusted Life Years; Trastuzumab | 2022 |
Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Platinum; Prospective Studies; Retrospective Studies; Stomach Neoplasms | 2023 |
Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer.
Topics: Carcinoembryonic Antigen; Esophageal Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Neoplasms, Second Primary; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies | 2023 |
The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Platinum; Retrospective Studies | 2023 |
Cancer cell membrane fused liposomal platinum(IV) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Cisplatin; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Platinum; Prodrugs | 2023 |
Platinum(II) ring-fused chlorins as efficient theranostic agents: Dyes for tumor-imaging and photodynamic therapy of cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Fluorescent Dyes; Humans; Melanoma; Molecular Structure; Optical Imaging; Photochemotherapy; Platinum; Porphyrins; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2020 |
Carcinostatic effects of alkanoyl ascorbate plus platinum nano-colloid and stabilization of the esterolytically resultant ascorbate by hydrogen.
Topics: Antineoplastic Agents; Ascorbic Acid; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colloids; Esophageal Neoplasms; Humans; Hydrogen; Nanocomposites; Platinum; Water | 2021 |
Postoperative adjuvant therapy for resectable esophageal cancer: A protocol of a systematic review and meta-analysis.
Topics: Adult; B7-H1 Antigen; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Humans; Immunotherapy; Meta-Analysis as Topic; Outcome Assessment, Health Care; Platinum; Postoperative Period; Programmed Cell Death 1 Receptor; Systematic Reviews as Topic | 2019 |
Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Esophageal Neoplasms; Hospitals, Community; Humans; Irinotecan; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromogranins; Esophageal Neoplasms; Female; Follow-Up Studies; Genotype; GTP-Binding Protein alpha Subunits, Gs; Homozygote; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Survival Rate | 2014 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Computational Biology; DNA Copy Number Variations; Esophageal Neoplasms; Evolution, Molecular; Exome; Gene Amplification; Genetic Variation; Genome, Human; Genomic Instability; Genomics; Humans; Mutation; Neoadjuvant Therapy; Platinum | 2015 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; France; Humans; Incidence; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2015 |
A germline predictive signature of response to platinum chemotherapy in esophageal cancer.
Topics: Aged; Esophageal Neoplasms; Female; Germ Cells; Humans; Male; Middle Aged; Models, Genetic; Multidrug Resistance-Associated Protein 2; Neoadjuvant Therapy; Platinum; Polymorphism, Single Nucleotide; ROC Curve | 2016 |
Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy.
Topics: Asian People; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Demography; Disease-Free Survival; DNA Repair; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Platinum; Polymorphism, Single Nucleotide; Prognosis; ROC Curve | 2016 |
Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Retreatment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
Eradication and palliation of squamous cell carcinoma of the esophagus with chemotherapy, radiotherapy, and surgical therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycins; Platinum | 1981 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
[Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Platinum; Tissue Distribution | 2001 |
Analysis of tissue platinum distribution in patients with cancer of the oesophagus.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophagus; Humans; Male; Middle Aged; Platinum | 1991 |